Biotechnology company focused on developing precision oncology therapies targeting difficult-to-treat cancers.
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical firm, specializes in advancing treatments for allergic and inflammatory diseases. Its primary focus is on developing THB001, an innovative oral small-molecule KIT inhibitor aimed at addressing chronic urticaria. This dermatologic condition, characterized by mast cell activation leading to red, itchy welts or hives, represents a significant area of unmet medical need for which Third Harmonic Bio is seeking to provide effective therapeutic solutions.
THB001 is not only being developed for chronic urticaria but also holds promise for treating conditions affecting the airway and gastrointestinal tract. The company's approach leverages its expertise in small-molecule therapies to target the underlying mechanisms driving these allergic and inflammatory responses.
Formerly known as Project IGE, Inc., Third Harmonic Bio underwent a name change in June 2019, reflecting its commitment to advancing innovative therapies in the biopharmaceutical landscape. Founded in 2019 and headquartered in Cambridge, Massachusetts, the company operates with a clear mission to improve the lives of patients suffering from chronic urticaria and related allergic conditions through its pioneering research and development efforts.
Driven by a dedicated team of scientists and professionals, Third Harmonic Bio continues to expand its portfolio of therapeutic candidates aimed at addressing a spectrum of allergic and inflammatory diseases. With its strategic location in Cambridge, a hub renowned for biopharmaceutical innovation, the company remains poised to make significant strides in advancing novel treatments to benefit patients worldwide.